Gudi R - Search Results

1

FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC Trial.

Pulte ED, Chen H, Price LSL, Gudi R, Li H, Okusanya OO, Ma L, Rodriguez L, Vallejo J, Norsworthy KJ, de Claro RA, Theoret MR, Pazdur R. Pulte ED, et al. Among authors: gudi r. Oncologist. 2022 Mar 4;27(2):149-157. doi: 10.1093/oncolo/oyab040. Oncologist. 2022. PMID: 35641211 Free PMC article.

2

FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation.

Pulte ED, Norsworthy KJ, Wang Y, Xu Q, Qosa H, Gudi R, Przepiorka D, Fu W, Okusanya OO, Goldberg KB, De Claro RA, Farrell AT, Pazdur R. Pulte ED, et al. Among authors: gudi r. Clin Cancer Res. 2021 Jul 1;27(13):3515-3521. doi: 10.1158/1078-0432.CCR-20-4271. Epub 2021 Feb 25. Clin Cancer Res. 2021. PMID: 33632926 Free PMC article. Clinical Trial.

3

FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy.

Przepiorka D, Le RQ, Ionan A, Li RJ, Wang YH, Gudi R, Mitra S, Vallejo J, Okusanya OO, Ma L, Yang Y, Patel P, Mezaache D, Shah R, Banerjee A, McLamore S, Maung AN, Goldberg KB, Pazdur R, Theoret MR, De Claro RA. Przepiorka D, et al. Among authors: gudi r. Clin Cancer Res. 2022 Jun 13;28(12):2488-2492. doi: 10.1158/1078-0432.CCR-21-4176. Clin Cancer Res. 2022. PMID: 35135839 Free PMC article.

4

FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma.

Miller BW, Przepiorka D, de Claro RA, Lee K, Nie L, Simpson N, Gudi R, Saber H, Shord S, Bullock J, Marathe D, Mehrotra N, Hsieh LS, Ghosh D, Brown J, Kane RC, Justice R, Kaminskas E, Farrell AT, Pazdur R. Miller BW, et al. Among authors: gudi r. Clin Cancer Res. 2015 Apr 1;21(7):1525-9. doi: 10.1158/1078-0432.CCR-14-2522. Epub 2015 Feb 2. Clin Cancer Res. 2015. PMID: 25645861

5

FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.

Norsworthy KJ, Luo L, Hsu V, Gudi R, Dorff SE, Przepiorka D, Deisseroth A, Shen YL, Sheth CM, Charlab R, Williams GM, Goldberg KB, Farrell AT, Pazdur R. Norsworthy KJ, et al. Among authors: gudi r. Clin Cancer Res. 2019 Jun 1;25(11):3205-3209. doi: 10.1158/1078-0432.CCR-18-3749. Epub 2019 Jan 28. Clin Cancer Res. 2019. PMID: 30692099

6

FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.

Przepiorka D, Luo L, Subramaniam S, Qiu J, Gudi R, Cunningham LC, Nie L, Leong R, Ma L, Sheth C, Deisseroth A, Goldberg KB, Blumenthal GM, Pazdur R. Przepiorka D, et al. Among authors: gudi r. Oncologist. 2020 Feb;25(2):e328-e334. doi: 10.1634/theoncologist.2019-0627. Epub 2019 Oct 22. Oncologist. 2020. PMID: 32043777 Free PMC article.

7

An FDA oncology analysis of immune activating products and first-in-human dose selection.

Saber H, Gudi R, Manning M, Wearne E, Leighton JK. Saber H, et al. Among authors: gudi r. Regul Toxicol Pharmacol. 2016 Nov;81:448-456. doi: 10.1016/j.yrtph.2016.10.002. Epub 2016 Oct 13. Regul Toxicol Pharmacol. 2016. PMID: 27743776

8

Health assessment of gasoline and fuel oxygenate vapors: micronucleus and sister chromatid exchange evaluations.

Schreiner CA, Hoffman GM, Gudi R, Clark CR. Schreiner CA, et al. Among authors: gudi r. Regul Toxicol Pharmacol. 2014 Nov;70(2 Suppl):S29-34. doi: 10.1016/j.yrtph.2014.05.014. Epub 2014 May 20. Regul Toxicol Pharmacol. 2014. PMID: 24852491 Free article.

9

Surveillance results of depleted uranium-exposed Gulf War I veterans: sixteen years of follow-up.

McDiarmid MA, Engelhardt SM, Dorsey CD, Oliver M, Gucer P, Wilson PD, Kane R, Cernich A, Kaup B, Anderson L, Hoover D, Brown L, Albertini R, Gudi R, Squibb KS. McDiarmid MA, et al. Among authors: gudi r. J Toxicol Environ Health A. 2009;72(1):14-29. doi: 10.1080/15287390802445400. J Toxicol Environ Health A. 2009. PMID: 18979351

10

Assessment of the in vivo aneuploidy/micronucleus assay in mouse bone marrow cells with 16 chemicals.

Gudi R, Xu J, Thilagar A. Gudi R, et al. Environ Mol Mutagen. 1992;20(2):106-16. doi: 10.1002/em.2850200206. Environ Mol Mutagen. 1992. PMID: 1505527

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

79 results

Search Page